1. Home
  2. Detail

@mikemalagies: Pray with me tonight for fear #christiantiktok #Jesus #prayer #jesuslovesyou

Mike Malagies
Mike Malagies
Open In TikTok:
Region: US
Tuesday 11 October 2022 01:38:04 GMT
2455
718
43
56

Music

Download

No Watermark .mp4 (10.36MB) No Watermark(HD) .mp4 (3.66MB) Watermark .mp4 (10.18MB) Music .mp3

Comments

tayy391
tayy 🤍 :
Amen ❤️🙏
2022-10-11 02:26:18
4
davidzt200
SilentDave™️ :
❤❤❤
2022-10-14 01:30:09
3
taylormeaders
Taylor Meaders :
🙏🏽🙏🏽🙏🏽
2022-10-11 03:28:33
4
To see more videos from user @mikemalagies, please go to the Tikwm homepage.

Other Videos

#🚩✌️jeay_sindh_🚩✌️ #😁 #pppppppppp #yyyyyy #yp
#🚩✌️jeay_sindh_🚩✌️ #😁 #pppppppppp #yyyyyy #yp
Two big study updates presented at ESMO on adjuvant ribociclib and abemaciclib (CDK 4/6 inhibitors) in early stage breast cancer. All explained in my Substack. Go to drteplinsky.substack.com. Bottom line if you just want the cliff notes: ⭐️ Ribociclib (Kisqali): At a median follow-up of 55.4 months, absolute improvement in invasive disease free survival (survival without disease) was 4.5% in patients receiving ribociclib (81% in endocrine therapy alone versus 85.5% in ribociclib+ET). ⭐️ Abemaciclib (Verzenio): 7 year overall survival was 86.8% with abemaciclib-ET and 85.0% with ET (absolute difference, 1.8%). This translates into a 15.8% lower risk of death with abemaciclib + endocrine therapy compared to endocrine therapy alone. Invasive disease free survival was improved by 6.5% at the 7 year mark with the addition of abemaciclib. Additionally, there is a significant difference in the numbers of patients who have developed a distant recurrence and are being treated for metastatic disease (there are 33% fewer patients living with metastatic disease: 180 vs 266 in the group treated with abemaciclib). Over time, this may lead to a further reduction in death from breast cancer. For all the details and nuanced info, check out the substack! @esmo_eur_oncology #esmo25 #cdk #breastcancer #kisqali #verzenio
Two big study updates presented at ESMO on adjuvant ribociclib and abemaciclib (CDK 4/6 inhibitors) in early stage breast cancer. All explained in my Substack. Go to drteplinsky.substack.com. Bottom line if you just want the cliff notes: ⭐️ Ribociclib (Kisqali): At a median follow-up of 55.4 months, absolute improvement in invasive disease free survival (survival without disease) was 4.5% in patients receiving ribociclib (81% in endocrine therapy alone versus 85.5% in ribociclib+ET). ⭐️ Abemaciclib (Verzenio): 7 year overall survival was 86.8% with abemaciclib-ET and 85.0% with ET (absolute difference, 1.8%). This translates into a 15.8% lower risk of death with abemaciclib + endocrine therapy compared to endocrine therapy alone. Invasive disease free survival was improved by 6.5% at the 7 year mark with the addition of abemaciclib. Additionally, there is a significant difference in the numbers of patients who have developed a distant recurrence and are being treated for metastatic disease (there are 33% fewer patients living with metastatic disease: 180 vs 266 in the group treated with abemaciclib). Over time, this may lead to a further reduction in death from breast cancer. For all the details and nuanced info, check out the substack! @esmo_eur_oncology #esmo25 #cdk #breastcancer #kisqali #verzenio
リズム感覚壊滅的でごめんなさい；；；； #y2k #ニーハイ #ボブ #轟はじめ #踊ってみた
リズム感覚壊滅的でごめんなさい；；；； #y2k #ニーハイ #ボブ #轟はじめ #踊ってみた
Always a fan of Monday nights @ikin_dance 💘⭐️ What a way to kick off term3 ##dancelife##openclass##myfav##fyp
Always a fan of Monday nights @ikin_dance 💘⭐️ What a way to kick off term3 ##dancelife##openclass##myfav##fyp


#singaporetiktokers🇸🇬 #malaysiatiktok🇲🇾 #creatorsearchinsights #malaysiatiktok #sss_creations
#singaporetiktokers🇸🇬 #malaysiatiktok🇲🇾 #creatorsearchinsights #malaysiatiktok #sss_creations

About

Legal